John JD - Ocugen General Counsel
| OCGN Stock | USD 0.91 0.03 3.19% |
Executive
John JD is General Counsel of Ocugen Inc
| Phone | 484 328 4701 |
| Web | https://www.ocugen.com |
Ocugen Management Efficiency
The company has return on total asset (ROA) of (0.4798) % which means that it has lost $0.4798 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0329) %, meaning that it created substantial loss on money invested by shareholders. Ocugen's management efficiency ratios could be used to measure how well Ocugen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert Yang | Elevation Oncology | N/A | |
| Sean Tucker | Vaxart Inc | 56 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| David Brady | Zura Bio Limited | N/A | |
| Robert MD | Novavax | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Biren Shah | Elevation Oncology | N/A | |
| Edward Berg | Vaxart Inc | 60 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Rajesh Kapoor | Vaxart Inc | N/A | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Erika Trahan | Novavax | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| Shaily Garg | Vaxart Inc | N/A | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| JD Esq | Novavax | 53 | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
Management Performance
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.48 |
Ocugen Inc Leadership Team
Elected by the shareholders, the Ocugen's board of directors comprises two types of representatives: Ocugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ocugen. The board's role is to monitor Ocugen's management team and ensure that shareholders' interests are well served. Ocugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ocugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Sr Officer | ||
| CMA CPA, Chief Officer | ||
| Michael Shine, VP Commercial | ||
| Michael MBA, Senior Commercial | ||
| Shankar MBA, CEO CoFounder | ||
| Durgaprasad Annavajjula, Head VP | ||
| Arun Upadhyay, Chief Development | ||
| Uday Kompella, Cofounder Director | ||
| CMI MD, Chief Officer | ||
| John JD, General Counsel | ||
| Jyothy MS, Head Quality | ||
| Tiffany MBA, Head Communications | ||
| Zara Gaudioso, Head AVP | ||
| MBA MBA, Chairman CoFounder | ||
| Vijay Tammara, VP Quality | ||
| FACP MD, Chief Officer | ||
| Kristen Craft, Head Culture |
Ocugen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ocugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (11.67) % | ||||
| Current Valuation | 254.19 M | ||||
| Shares Outstanding | 291.32 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 27.52 % | ||||
| Number Of Shares Shorted | 54.4 M | ||||
| Price To Earning | (1.81) X | ||||
| Price To Book | 7.04 X |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.